217 related articles for article (PubMed ID: 33087024)
1. Novel Nano Carriers for the Treatment of Progressive Auto Immune Disease Rheumatoid Arthritis.
Mishra R; Gupta S
Curr Pharm Des; 2021; 27(21):2468-2481. PubMed ID: 33087024
[TBL] [Abstract][Full Text] [Related]
2. Targeted drug-delivery systems in the treatment of rheumatoid arthritis: recent advancement and clinical status.
Gorantla S; Singhvi G; Rapalli VK; Waghule T; Dubey SK; Saha RN
Ther Deliv; 2020 Apr; 11(4):269-284. PubMed ID: 32434463
[TBL] [Abstract][Full Text] [Related]
3. Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort.
Shu J; Bykerk VP; Boire G; Haraoui B; Hitchon C; Thorne JC; Tin D; Keystone EC; Pope JE;
J Rheumatol; 2015 Nov; 42(11):2023-8. PubMed ID: 26329342
[TBL] [Abstract][Full Text] [Related]
4. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
de Vries-Bouwstra JK; Goekoop-Ruiterman YP; Verpoort KN; Schreuder GM; Ewals JA; Terwiel JP; Ronday HK; Kerstens PJ; Toes RE; de Vries RR; Breedveld FC; Dijkmans BA; Huizinga TW; Allaart CF
Arthritis Rheum; 2008 May; 58(5):1293-8. PubMed ID: 18438829
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy.
Alam J; Jantan I; Bukhari SNA
Biomed Pharmacother; 2017 Aug; 92():615-633. PubMed ID: 28582758
[TBL] [Abstract][Full Text] [Related]
6. Novel drug delivery systems for NSAIDs in management of rheumatoid arthritis: An overview.
Thakur S; Riyaz B; Patil A; Kaur A; Kapoor B; Mishra V
Biomed Pharmacother; 2018 Oct; 106():1011-1023. PubMed ID: 30119166
[TBL] [Abstract][Full Text] [Related]
7. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
8. Associations of rheumatoid factor and anti-citrullinated peptide antibody with disease progression and treatment outcomes in patients with rheumatoid arthritis.
Katchamart W; Koolvisoot A; Aromdee E; Chiowchanwesawakit P; Muengchan C
Rheumatol Int; 2015 Oct; 35(10):1693-9. PubMed ID: 25903353
[TBL] [Abstract][Full Text] [Related]
9. Antibodies against cyclic citrullinated peptide don't decrease after 6 months of infliximab treatment in refractory rheumatoid arthritis.
Kolarz B; Majdan M; Dryglewska M; Darmochwal-Kolarz D
Rheumatol Int; 2011 Nov; 31(11):1439-43. PubMed ID: 20473501
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery targets and systems for targeted treatment of rheumatoid arthritis.
Feng X; Chen Y
J Drug Target; 2018 Dec; 26(10):845-857. PubMed ID: 29376442
[TBL] [Abstract][Full Text] [Related]
11. ACPA Antibodies Titer at the Time of Rheumatoid Arthritis Diagnosis Is Not Associated with Disease Severity.
Shpatz R; Braun-Moscovici Y; Balbir-Gurman A
Isr Med Assoc J; 2021 Oct; 23(10):646-650. PubMed ID: 34672447
[TBL] [Abstract][Full Text] [Related]
12. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
[TBL] [Abstract][Full Text] [Related]
13. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis.
Gottenberg JE; Courvoisier DS; Hernandez MV; Iannone F; Lie E; Canhão H; Pavelka K; Hetland ML; Turesson C; Mariette X; Finckh A
Arthritis Rheumatol; 2016 Jun; 68(6):1346-52. PubMed ID: 26815727
[TBL] [Abstract][Full Text] [Related]
14. Outcome of patients with early arthritis without rheumatoid factor and ACPA and predictors of rheumatoid arthritis in the ESPOIR cohort.
Mouterde G; Rincheval N; Lukas C; Daien C; Saraux A; Dieudé P; Morel J; Combe B
Arthritis Res Ther; 2019 Jun; 21(1):140. PubMed ID: 31171038
[TBL] [Abstract][Full Text] [Related]
15. Repeat serological testing for anti-citrullinated peptide antibody after commencement of therapy is not helpful in patients with seronegative rheumatoid arthritis.
Reid AB; Wiese M; McWilliams L; Metcalf R; Hall C; Lee A; Hill C; Wechalekar M; Cleland L; Proudman SM
Intern Med J; 2020 Jul; 50(7):818-822. PubMed ID: 32656986
[TBL] [Abstract][Full Text] [Related]
16. Nano-platform Strategies of Herbal Components for the Management of Rheumatoid Arthritis: A Review on the Battle for Next-Generation Formulations.
Prabha J; Kumar M; Kumar D; Chopra S; Bhatia A
Curr Drug Deliv; 2024; 21(8):1082-1105. PubMed ID: 37622715
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy.
Han Y; Huang S
J Control Release; 2023 Apr; 356():142-161. PubMed ID: 36863691
[TBL] [Abstract][Full Text] [Related]
18. Does immunological remission, defined as disappearance of autoantibodies, occur with current treatment strategies? A long-term follow-up study in rheumatoid arthritis patients who achieved sustained DMARD-free status.
Boeters DM; Burgers LE; Toes RE; van der Helm-van Mil A
Ann Rheum Dis; 2019 Nov; 78(11):1497-1504. PubMed ID: 31413004
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum rheumatoid factor, anti-citrullinated protein antibodies and active rheumatoid arthritis disease are not associated with chronic periodontitis.
Che Rahim MJ; Wan Mohamad WM; Saddki N; Taib H; Wan Abhamid WZ; Wong KK; Wan Ghazali WS
Malays J Pathol; 2019 Dec; 41(3):267-272. PubMed ID: 31901911
[TBL] [Abstract][Full Text] [Related]
20. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis.
Bos WH; Bartelds GM; Wolbink GJ; de Koning MH; van de Stadt RJ; van Schaardenburg D; Dijkmans BA; Nurmohamed MT
J Rheumatol; 2008 Oct; 35(10):1972-7. PubMed ID: 18785316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
